These procedures are commonplace among celebrities and those seeking treatments in Gangnam, an insider revealed. Public interest in stem cells skyrocketed last summer when global icon Kim Kardashian disclosed her experience with regenerative medical treatments in South Korea. Once primarily associated with treating joint issues and rare, hard-to-cure diseases, stem cell therapies have rapidly expanded into everyday beauty and wellness applications, including skin rejuvenation, anti-aging, and hair loss treatments.
As celebrities and influencers share their experiences with these treatments on social media, the public has become increasingly familiar with the topic. Responding to this growing demand, medical facilities are swiftly expanding their offerings of non-covered stem cell procedures. These treatments now span a wide range of applications, from skin regeneration and hair restoration to arthritis management and chronic pain relief.
However, it’s crucial to understand that not all technologies labeled as stem cell treatments in the medical field are equivalent. The term encompasses a variety of approaches, including stem cell therapies approved by South Korea’s Ministry of Food and Drug Safety (MFDS), medical practices using a patient’s own blood or fat tissue, and non-covered procedures classified as emerging medical technologies.
For the average patient, it can be extremely difficult to discern whether the treatment they’re receiving is an approved drug, a medical procedure, or still in the process of gathering clinical evidence.
Medical professionals view the increasing demand for regenerative medicine as a natural progression as we enter an ultra-aged society. However, they acknowledge that the confusion among consumers, caused by different technologies being marketed under the same umbrella term, is a significant issue that needs to be addressed.
Despite Sharing Stem Cell Treatment Label, These Therapies Differ Widely in Their Underlying Principles and Regulatory Oversight.
A closer look at the technologies marketed as stem cell procedures in hospitals reveals significant variations. These include Platelet-Rich Plasma (PRP), which concentrates platelets from a patient’s own blood; Platelet-Rich Fibrin(PRF), utilizing both platelets and fibrin; and Stromal Vascular Fraction (SVF), which isolates various cells from fat tissue. Some facilities even offer MFDS-approved stem cell therapies.
While these treatments may share similar names, their mechanisms of action differ substantially. PRP and PRF harness growth factors from platelets to promote tissue healing, without directly using stem cells. SVF employs a mixture of cells isolated from fat tissue. In contrast, approved stem cell therapies undergo rigorous manufacturing processes and are evaluated for quality, safety, and efficacy as pharmaceutical products.
A leading expert in regenerative medicine explained that patients often assume all stem cell treatments are identical, but they can be either drugs or medical procedures. Even when sharing the same name, these treatments can differ significantly in terms of applicable regulations, oversight, and the level of clinical evidence supporting them.
In South Korea, stem cell technologies are regulated under different frameworks. MFDS-approved stem cell therapies include treatments for conditions such as knee cartilage defects and complex Crohn’s disease fistulas.
On the other hand, medical technologies using stem cells may be implemented as medical practices after undergoing evaluations, while some are developed through clinical research under advanced regenerative medicine protocols. As of now, no treatments using stem cells have been approved under these advanced regulations.
In essence, even when the term stem cell is used, the applicable regulations and verification processes can vary widely depending on whether it’s classified as a drug or a medical procedure. Additionally, the level of clinical evidence supporting each technology and indication can differ significantly.
Another expert cautioned that it can’t generalize the effectiveness based solely on the term stem cell. The clinical evidence varies greatly depending on the specific condition being treated and the technology applied. It’s crucial to explain these distinctions clearly.
Despite Regulatory Distinctions, Patients Face a Black Box of Information… Government Plans to Establish Advertising Guidelines
The core issue is that average patients struggle to understand these nuances. Medical facilities often market various technologies under the broad umbrella of stem cell procedures. With advertisements primarily focusing on treatment outcomes, it becomes challenging for patients to verify the regulatory oversight and level of validation behind the treatments they’re considering.
Recognizing this confusion, the government is taking action. The Department of Health and Human Services aims to release advertising guidelines for regenerative medicine by mid-year. These guidelines will outline appropriate terminology for medical institutions when promoting regenerative medicine and key points for consumers to verify.
A government spokesperson stated that it understands that the public may perceive all of these as stem cell treatments. It’s developing comprehensive guidelines for regenerative medicine advertising to better inform both healthcare providers and the general public.
This year, the Department of Health and Human Services also conducted an audit of medical advertisements related to regenerative medicine. They scrutinized cases where unauthorized institutions advertised such procedures or promoted unapproved research and treatments. Even facilities designated for regenerative medicine must obtain separate approvals for their specific research or treatment protocols before implementation.
Medical practices involving stem cells are also subject to regulatory oversight. Novel medical technologies undergo safety and efficacy evaluations through new medical technology assessments. Technologies requiring further evidence may be implemented under specific conditions through a deferred evaluation system. In such cases, patients must be informed that the evidence is still being accumulated and provide informed consent.
Treatments Costing Tens to Hundreds of Millions of KRW Lack Transparency… Patients Deserve Informed Choices
Critics argue that the existence of regulations doesn’t necessarily translate to patients having access to adequate information. Many stem cell-related procedures are not covered by insurance, and costs can vary dramatically between providers. Yet, patients often lack objective data to compare the nature of treatments and their supporting clinical evidence.
A prominent expert in regenerative medicine observed that when buying a car, people meticulously compare performance, safety features, and warranty terms. However, stem cell procedures can cost anywhere from tens of millions to hundreds of millions of KRW (about 7,500 USD to 75,000 USD), yet consumers have far less information to objectively assess their validity and supporting evidence. The expert emphasized the need for an environment where patients receive comprehensive explanations about their treatments, including whether they are approved or experimental, and the strength of the supporting clinical data.
While regenerative medicine is emerging as a promising treatment frontier in the aging society, the field’s rapid growth underscores the importance of information transparency alongside technological advances. Rather than grouping diverse technologies under the broad term stem cell, it’s crucial for patients to understand the specific nature of their treatment, its level of validation, and the regulatory framework governing its use. This transparency is fundamental to building trust in the evolving regenerative medicine market.
